ME02509B - Proces za proizvodnju metansulfonatnih soli ralfinamida ili njihovih r-enantiomera - Google Patents

Proces za proizvodnju metansulfonatnih soli ralfinamida ili njihovih r-enantiomera

Info

Publication number
ME02509B
ME02509B MEP-2016-169A MEP16916A ME02509B ME 02509 B ME02509 B ME 02509B ME P16916 A MEP16916 A ME P16916A ME 02509 B ME02509 B ME 02509B
Authority
ME
Montenegro
Prior art keywords
production
enantiomers
salts
methanesulfonate salts
ralfinamide methanesulfonate
Prior art date
Application number
MEP-2016-169A
Other languages
German (de)
English (en)
French (fr)
Inventor
Claudio Giordano
Erwin Waldvogel
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of ME02509B publication Critical patent/ME02509B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

             Predmetni pronalazak se odnosi na novi proces za proizvodnju i(li) prečišćavanje soli metansulfonske kiseline i  (S)-2-[4-(2-fluorbenz i lo ksi )benz i lamino]propanamid a, tj. ralfinamida ili odgovarajućeg R-enantiomera u visokom prinosu i sa veoma visokom enantiomernom i hemijskom čistoćom, pri čemu su navedene soli suštinski oslobođene prisustva nečistoća sa genotoksičnim dejstvom i zaostataka rastvarača koji su poznati kao prekursori takvih jedinjenja.        
MEP-2016-169A 2010-04-27 2011-04-06 Proces za proizvodnju metansulfonatnih soli ralfinamida ili njihovih r-enantiomera ME02509B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10161207 2010-04-27
EP11714958.3A EP2563355B1 (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers
PCT/EP2011/055309 WO2011134763A1 (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers

Publications (1)

Publication Number Publication Date
ME02509B true ME02509B (me) 2017-02-20

Family

ID=42634917

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-169A ME02509B (me) 2010-04-27 2011-04-06 Proces za proizvodnju metansulfonatnih soli ralfinamida ili njihovih r-enantiomera

Country Status (28)

Country Link
US (2) US9505708B2 (me)
EP (1) EP2563355B1 (me)
JP (3) JP5808392B2 (me)
KR (1) KR101851118B1 (me)
CN (2) CN102858330B (me)
AR (1) AR085171A1 (me)
AU (1) AU2011246707B2 (me)
BR (1) BR112012027623B1 (me)
CA (1) CA2794389C (me)
CY (1) CY1117879T1 (me)
DK (1) DK2563355T3 (me)
EA (1) EA021389B1 (me)
ES (1) ES2590128T3 (me)
HK (2) HK1179881A1 (me)
HR (1) HRP20161077T1 (me)
HU (1) HUE030504T2 (me)
IL (1) IL222532A (me)
LT (1) LT2563355T (me)
ME (1) ME02509B (me)
MX (1) MX342697B (me)
NZ (2) NZ602648A (me)
PL (1) PL2563355T3 (me)
PT (1) PT2563355T (me)
RS (1) RS55084B1 (me)
SI (1) SI2563355T1 (me)
SM (1) SMT201600266B (me)
TW (1) TWI492919B (me)
WO (1) WO2011134763A1 (me)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ602648A (en) * 2010-04-27 2014-10-31 Newron Pharm Spa Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
CN103804341B (zh) * 2012-11-13 2018-04-10 中国人民解放军军事医学科学院毒物药物研究所 酰胺衍生物及其医药用途
CN104761531B (zh) * 2014-01-03 2017-12-01 中国人民解放军军事医学科学院毒物药物研究所 镇痛活性化合物及其医药用途
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
NZ531586A (en) 2001-09-03 2005-09-30 Newron Pharm Spa Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
CA2514574A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
KR101233711B1 (ko) 2003-08-25 2013-02-18 뉴론 파마슈티칼즈 에스. 피. 에이. 항염증제로서 유용한 알파-아미노아미드 유도체
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
PT1809271E (pt) * 2004-09-10 2010-08-30 Newron Pharm Spa Utilização de (halogenobenziloxi)benzilamino-propanamidas para o fabrico de medicamentos activos como moduladores selectivos dos canais de sódio e/ou de cálcio
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
DK2474521T3 (en) * 2006-06-19 2016-10-31 Newron Pharm Spa High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus
JP5315674B2 (ja) * 2007-11-19 2013-10-16 セントラル硝子株式会社 非水電池用電解液及びこれを用いた非水電池
SI2229351T1 (en) 2007-12-11 2018-02-28 Newron Pharmaceuticals S.P.A. PROCEDURE FOR PREPARATION OF 2- (4- (3-OR 2-FLUOROBENYLOXYL) BENZYLAMINO) PROPANAMIDES WITH A HIGH PURITY Purity
WO2009080470A1 (en) 2007-12-19 2009-07-02 Newron Pharmaceuticals S.P.A. Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
WO2009109334A1 (en) 2008-03-07 2009-09-11 Newron Pharmaceuticals S.P.A. (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
NZ602648A (en) * 2010-04-27 2014-10-31 Newron Pharm Spa Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers

Also Published As

Publication number Publication date
SMT201600266B (it) 2016-08-31
JP6345154B2 (ja) 2018-06-20
MX342697B (es) 2016-10-10
CA2794389A1 (en) 2011-11-03
EA021389B1 (ru) 2015-06-30
PL2563355T3 (pl) 2016-12-30
LT2563355T (lt) 2016-09-26
TW201139344A (en) 2011-11-16
IL222532A (en) 2017-09-28
NZ700221A (en) 2016-04-29
HRP20161077T1 (hr) 2016-10-21
BR112012027623B1 (pt) 2021-07-06
NZ602648A (en) 2014-10-31
DK2563355T3 (en) 2016-09-12
CN105037188A (zh) 2015-11-11
EP2563355A1 (en) 2013-03-06
MX2012012093A (es) 2012-12-17
EA201291116A1 (ru) 2013-04-30
JP2013528577A (ja) 2013-07-11
JP2017197553A (ja) 2017-11-02
IL222532A0 (en) 2012-12-31
RS55084B1 (sr) 2016-12-30
JP6450420B2 (ja) 2019-01-09
ES2590128T3 (es) 2016-11-18
HK1213872A1 (zh) 2016-07-15
BR112012027623A2 (pt) 2016-08-09
CY1117879T1 (el) 2017-05-17
CA2794389C (en) 2016-08-23
TWI492919B (zh) 2015-07-21
WO2011134763A1 (en) 2011-11-03
AR085171A1 (es) 2013-09-18
AU2011246707B2 (en) 2014-11-20
CN102858330A (zh) 2013-01-02
US9505708B2 (en) 2016-11-29
HK1179881A1 (en) 2013-10-11
SI2563355T1 (sl) 2016-10-28
US9856207B2 (en) 2018-01-02
US20130039983A1 (en) 2013-02-14
KR101851118B1 (ko) 2018-04-23
US20170029365A1 (en) 2017-02-02
EP2563355B1 (en) 2016-06-08
PT2563355T (pt) 2016-09-02
HUE030504T2 (en) 2017-05-29
JP5808392B2 (ja) 2015-11-10
CN105037188B (zh) 2017-06-23
JP2015180664A (ja) 2015-10-15
KR20130094212A (ko) 2013-08-23
CN102858330B (zh) 2015-07-22

Similar Documents

Publication Publication Date Title
EA202090917A1 (ru) Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение
ME01618B (me) Novi proces za dobijanje derivata aminokiselina
ME02509B (me) Proces za proizvodnju metansulfonatnih soli ralfinamida ili njihovih r-enantiomera
EA201790916A1 (ru) Новые лиганды rig-i и способы их получения
IT1401911B1 (it) Processo per la sintesi di acido 2,5-furandicarbossilico
BR112012032244A2 (pt) processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes
BRPI0823162A2 (pt) Processo destinado à produção de ácido forsfórico de alta pureza
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
BR112017028322A2 (pt) compostos, processo para a produção de compostos i, para a produção de compostos ii dos compostos iii e para a produção de compostos iii, compostos intermediários v e utilização dos compostos i
BR112014010416A2 (pt) processo de produção de acrilato de 2-octila por esterificação direta
BR112018073490A2 (pt) 6.7.beta-epóxidos esteroides como intermediários químicos
PH12014502453A1 (en) Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)- chromen-4-one derivatives and their use in preparing pharmaceuticals
BR112016013640A8 (pt) moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos
UA111868C2 (uk) Спосіб одержання естерів (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)-оцтової кислоти
BR112012013582A2 (pt) processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
BR112017017066A2 (pt) método de preparação para praziquantel e compostos intermediários do mesmo
CO6430457A2 (es) Proceso para la preparación de amidas del ácido pirazol carboxilico
ME00927B (me) Novi postupak za sintezu agomelatina
BR112012031086A2 (pt) intermediários de agomelatina e método de preparação dos mesmos
UY35766A (es) Proceso industrial para la síntesis de ingredientes activos esteroides
BR112015015880A2 (pt) processo para a produção do composto, composto de fórmula, preparação farmacêutica e compostos, composições, métodos e utilizações substancialmente inovadores
BR112012014416A2 (pt) novos derivados de dioxolanos e de dioxanos, e método para sua produção.
FR2970000B1 (fr) Nouveau procede de synthese de l'agomelatine
BR112014012595A2 (pt) processo de racemização de ácido (s)-3-carbamoilmetil-5-metil-hexanoico
BR112014013515A2 (pt) processo para a produção de morfinanos de lactama de sete elementos